TY - JOUR AU - Kennedy, Laura C. AU - Gadi, Vijayakrishna PY - 2018 TI - Dasatinib in breast cancer: Src-ing for response in all the wrong kinases JF - Annals of Translational Medicine; Vol 6, Supplement 1 (November 29, 2018): Annals of Translational Medicine Y2 - 2018 KW - N2 - Src is a non-receptor tyrosine kinase that has been associated with carcinogenesis, impairs osteoclast bone resorption, enhances angiogenesis in vivo , and plays a role in the development of breast cancer bone metastases (1-3). Writing in Clinical Breast Cancer , Morris et al . present the results of a single-arm phase II clinical trial evaluating a combination of paclitaxel and dasatinib, a Src inhibitor, in patients with HER2-negative metastatic breast cancer (4). UR - https://atm.amegroups.org/article/view/22018